Deciphera Pharmaceuticals (DCPH)
(Delayed Data from NSDQ)
$25.37 USD
0.00 (0.00%)
Updated May 9, 2024 04:00 PM ET
After-Market: $25.38 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Deciphera Pharmaceuticals, Inc. (DCPH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$26.09 | $30.00 | $23.00 | 2.84% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Deciphera Pharmaceuticals, Inc. comes to $26.09. The forecasts range from a low of $23.00 to a high of $30.00. The average price target represents an increase of 2.84% from the last closing price of $25.37.
Analyst Price Targets (9 )
Broker Rating
Deciphera Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.60 a month ago based on 10 recommendations.
Of the nine recommendations deriving the current ABR, three are Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 8 | 7 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 6 | 6 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 1 | 1 | 1 |
ABR | 2.33 | 2.33 | 1.60 | 1.67 | 1.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/30/2024 | JMP Securities | Reni Benjamin | Strong Buy | Hold |
4/30/2024 | Guggenheim Securities | Michael Schmidt | Strong Buy | Hold |
4/29/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Hold |
4/29/2024 | SVB Securities | Andrew Berens | Strong Buy | Hold |
2/7/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.33 |
ABR (Last week) | 2.33 |
# of Recs in ABR | 9 |
Average Target Price | $26.09 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | -0.55 |